View Future GrowthDr.Finance 과거 순이익 실적과거 기준 점검 0/6Dr.Finance 의 수입은 연평균 -32.9%의 비율로 감소해 온 반면, Capital Markets 산업은 연평균 6.7%의 비율로 감소했습니다. 매출은 연평균 8.2%의 비율로 감소해 왔습니다.핵심 정보-32.89%순이익 성장률-32.89%주당순이익(EPS) 성장률Capital Markets 산업 성장률9.44%매출 성장률-8.15%자기자본이익률-227.31%순이익률-6.49%다음 순이익 업데이트13 Aug 2026최근 과거 실적 업데이트공고 • May 27Dr.Finance S.A. to Report Fiscal Year 2025 Results on May 26, 2026Dr.Finance S.A. announced that they will report fiscal year 2025 results on May 26, 2026공고 • May 26+ 1 more updateDr.Finance S.A. to Report Q2, 2026 Results on Aug 13, 2026Dr.Finance S.A. announced that they will report Q2, 2026 results on Aug 13, 2026Reported Earnings • Oct 22Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł2.39m (down 7.2% from 3Q 2024). Net loss: zł106.8k (loss widened 2.8% from 3Q 2024).Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł2.40m (up 4.9% from 2Q 2024). Net income: zł130.2k (up zł274.4k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł2.12m (down 28% from 1Q 2024). Net loss: zł108.8k (loss widened 91% from 1Q 2024).Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł2.29m (up 88% from 2Q 2023). Net loss: zł144.2k (loss widened 248% from 2Q 2023).모든 업데이트 보기Recent updates공고 • Jun 03Dr.Finance S.A., Annual General Meeting, Jun 26, 2026Dr.Finance S.A., Annual General Meeting, Jun 26, 2026, at 10:00 Central European Standard Time.공고 • May 27Dr.Finance S.A. to Report Fiscal Year 2025 Results on May 26, 2026Dr.Finance S.A. announced that they will report fiscal year 2025 results on May 26, 2026공고 • May 26+ 1 more updateDr.Finance S.A. to Report Q2, 2026 Results on Aug 13, 2026Dr.Finance S.A. announced that they will report Q2, 2026 results on Aug 13, 2026New Risk • May 25New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: zł2.4m (US$667k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (zł2.4m revenue, or US$667k). Market cap is less than US$10m (zł6.81m market cap, or US$1.87m).New Risk • May 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.94m market cap, or US$1.35m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).New Risk • May 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.53m market cap, or US$1.26m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).Reported Earnings • Oct 22Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł2.39m (down 7.2% from 3Q 2024). Net loss: zł106.8k (loss widened 2.8% from 3Q 2024).Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł2.40m (up 4.9% from 2Q 2024). Net income: zł130.2k (up zł274.4k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł2.12m (down 28% from 1Q 2024). Net loss: zł108.8k (loss widened 91% from 1Q 2024).Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł2.29m (up 88% from 2Q 2023). Net loss: zł144.2k (loss widened 248% from 2Q 2023).공고 • Jun 05Dr.Finance S.A., Annual General Meeting, Jun 28, 2024Dr.Finance S.A., Annual General Meeting, Jun 28, 2024.Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.95m (up 296% from 1Q 2023). Net loss: zł57.0k (loss widened 400% from 1Q 2023).Reported Earnings • Feb 11Full year 2023 earnings released: zł0.002 loss per share (vs zł0.053 loss in FY 2022)Full year 2023 results: zł0.002 loss per share (improved from zł0.053 loss in FY 2022). Revenue: zł6.22m (down 17% from FY 2022). Net loss: zł7.7k (loss narrowed 96% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.공고 • Jan 12+ 4 more updatesDr.Finance S.A. to Report Fiscal Year 2023 Results on Nov 07, 2024Dr.Finance S.A. announced that they will report fiscal year 2023 results on Nov 07, 2024Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł1.51m (down 1.2% from 3Q 2022). Net income: zł28.1k (up zł33.5k from 3Q 2022). Profit margin: 1.9% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł1.21m (down 43% from 2Q 2022). Net loss: zł41.4k (loss narrowed 47% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.공고 • Jun 13Dr.Finance S.A., Annual General Meeting, Jun 29, 2023Dr.Finance S.A., Annual General Meeting, Jun 29, 2023, at 12:00 Central European Standard Time.공고 • Jan 12+ 4 more updatesDr.Finance S.A. to Report Q4, 2022 Results on Feb 13, 2023Dr.Finance S.A. announced that they will report Q4, 2022 results on Feb 13, 2023공고 • Nov 15Dr.Finance S.A. to Report Q3, 2022 Results on Nov 15, 2022Dr.Finance S.A. announced that they will report Q3, 2022 results on Nov 15, 2022Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.04, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 18x in the Capital Markets industry in Poland. Total returns to shareholders of 234% over the past three years.공고 • Jun 02Dr.Finance S.A., Annual General Meeting, Jun 27, 2022Dr.Finance S.A., Annual General Meeting, Jun 27, 2022, at 10:00 Central European Standard Time.Reported Earnings • Apr 27First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł2.97m (up 54% from 1Q 2021). Net loss: zł72.1k (loss widened 107% from 1Q 2021).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.09, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 173% over the past three years.Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.041 (up from zł0.004 loss in FY 2020). Revenue: zł11.7m (up 52% from FY 2020). Net income: zł154.5k (up zł168.0k from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Jan 19Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to zł1.07, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 161% over the past three years.Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.30, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 16x in the Capital Markets industry in Poland. Total returns to shareholders of 182% over the past three years.Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improved over the past weekAfter last week's 21% share price gain to zł1.39, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 202% over the past three years.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł1.24, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 187% over the past three years.Reported Earnings • Oct 19Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł3.49m (up 79% from 3Q 2020). Net income: zł191.4k (up 460% from 3Q 2020). Profit margin: 5.5% (up from 1.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 151 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 17First quarter 2021 earnings releasedThe company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: zł1.93m (up 12% from 1Q 2020). Net loss: zł34.9k (loss widened 166% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 124 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 17Full year 2020 earnings released: EPS zł0.012 (vs zł0.05 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: zł7.72m (up 7.5% from FY 2019). Net income: zł43.2k (down 77% from FY 2019). Profit margin: 0.6% (down from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.37, the stock is trading at a trailing P/E ratio of 60.4x, up from the previous P/E ratio of 52.5x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 270%.Valuation Update With 7 Day Price Move • Jan 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to zł1.33, the stock is trading at a trailing P/E ratio of 58.7x, down from the previous P/E ratio of 70.6x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 217%.공고 • Jan 13+ 2 more updatesDr.Finance S.A. to Report Q3, 2021 Results on Oct 15, 2021Dr.Finance S.A. announced that they will report Q3, 2021 results on Oct 15, 2021Is New 90 Day High Low • Dec 28New 90-day high: zł1.73The company is up 281% from its price of zł0.45 on 29 September 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.73, the stock is trading at a trailing P/E ratio of 76.3x, up from the previous P/E ratio of 66.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 220%.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.49, the stock is trading at a trailing P/E ratio of 65.7x, up from the previous P/E ratio of 55.6x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 239%.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to zł1.50, the stock is trading at a trailing P/E ratio of 66.2x, up from the previous P/E ratio of 54.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 200%.Valuation Update With 7 Day Price Move • Dec 07Market bids up stock over the past weekAfter last week's 16% share price gain to zł1.28, the stock is trading at a trailing P/E ratio of 56.5x, up from the previous P/E ratio of 48.5x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 156%.Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 15% share price decline to zł1.05, the stock is trading at a trailing P/E ratio of 46.3x, down from the previous P/E ratio of 54.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 102%.Valuation Update With 7 Day Price Move • Nov 10Market bids up stock over the past weekAfter last week's 24% share price gain to zł1.23, the stock is trading at a trailing P/E ratio of 54.2x, up from the previous P/E ratio of 43.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 128%.Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 45% share price gain to zł1.41, the stock is trading at a trailing P/E ratio of 62.2x, up from the previous P/E ratio of 42.8x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 182%.Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 33% share price decline to zł1.10, the stock is trading at a trailing P/E ratio of 48.5x, down from the previous P/E ratio of 72.8x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 112%.Valuation Update With 7 Day Price Move • Oct 19Market bids up stock over the past weekAfter last week's 79% share price gain to zł1.65, the stock is trading at a trailing P/E ratio of 72.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 206%.Reported Earnings • Oct 15Third quarter earnings releasedOver the last 12 months the company has reported total profits of zł84.8k, down 53% from the prior year. Total revenue was zł7.29m over the last 12 months, up 5.8% from the prior year.Is New 90 Day High Low • Oct 12New 90-day high: zł0.92The company is up 109% from its price of zł0.44 on 14 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 6.0% over the same period.매출 및 비용 세부 내역Dr.Finance가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:DRF 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 26203031 Dec 25505030 Sep 25909030 Jun 251009031 Mar 25909031 Dec 2410010030 Sep 2411010030 Jun 24909031 Mar 24808031 Dec 23606030 Sep 23404030 Jun 23404031 Mar 23505031 Dec 22707030 Sep 2210010030 Jun 2212011031 Mar 2213012031 Dec 2112011030 Sep 2110010030 Jun 21908031 Mar 21808031 Dec 20807030 Sep 20707030 Jun 20707031 Mar 20707031 Dec 19707030 Sep 19706030 Jun 19606031 Mar 19505031 Dec 18505030 Sep 18514030 Jun 18515031 Mar 18505031 Dec 17605030 Sep 17605030 Jun 17605031 Mar 17605031 Dec 16605030 Sep 16505030 Jun 16505031 Mar 16504031 Dec 15404030 Sep 154040양질의 수익: DRF 은(는) 현재 수익성이 없습니다.이익 마진 증가: DRF는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: DRF은 수익성이 없으며 지난 5년 동안 손실이 연평균 32.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 DRF의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: DRF은 수익성이 없어 지난 해 수익 성장률을 Capital Markets 업계(40.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: DRF는 현재 수익성이 없으므로 자본 수익률이 음수(-227.31%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/12 22:05종가2026/08/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Dr.Finance S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • May 27Dr.Finance S.A. to Report Fiscal Year 2025 Results on May 26, 2026Dr.Finance S.A. announced that they will report fiscal year 2025 results on May 26, 2026
공고 • May 26+ 1 more updateDr.Finance S.A. to Report Q2, 2026 Results on Aug 13, 2026Dr.Finance S.A. announced that they will report Q2, 2026 results on Aug 13, 2026
Reported Earnings • Oct 22Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł2.39m (down 7.2% from 3Q 2024). Net loss: zł106.8k (loss widened 2.8% from 3Q 2024).
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł2.40m (up 4.9% from 2Q 2024). Net income: zł130.2k (up zł274.4k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł2.12m (down 28% from 1Q 2024). Net loss: zł108.8k (loss widened 91% from 1Q 2024).
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł2.29m (up 88% from 2Q 2023). Net loss: zł144.2k (loss widened 248% from 2Q 2023).
공고 • Jun 03Dr.Finance S.A., Annual General Meeting, Jun 26, 2026Dr.Finance S.A., Annual General Meeting, Jun 26, 2026, at 10:00 Central European Standard Time.
공고 • May 27Dr.Finance S.A. to Report Fiscal Year 2025 Results on May 26, 2026Dr.Finance S.A. announced that they will report fiscal year 2025 results on May 26, 2026
공고 • May 26+ 1 more updateDr.Finance S.A. to Report Q2, 2026 Results on Aug 13, 2026Dr.Finance S.A. announced that they will report Q2, 2026 results on Aug 13, 2026
New Risk • May 25New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: zł2.4m (US$667k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (zł2.4m revenue, or US$667k). Market cap is less than US$10m (zł6.81m market cap, or US$1.87m).
New Risk • May 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.94m market cap, or US$1.35m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).
New Risk • May 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (zł4.53m market cap, or US$1.26m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (zł9.4m revenue, or US$2.6m).
Reported Earnings • Oct 22Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł2.39m (down 7.2% from 3Q 2024). Net loss: zł106.8k (loss widened 2.8% from 3Q 2024).
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł2.40m (up 4.9% from 2Q 2024). Net income: zł130.2k (up zł274.4k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 17First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł2.12m (down 28% from 1Q 2024). Net loss: zł108.8k (loss widened 91% from 1Q 2024).
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł2.29m (up 88% from 2Q 2023). Net loss: zł144.2k (loss widened 248% from 2Q 2023).
공고 • Jun 05Dr.Finance S.A., Annual General Meeting, Jun 28, 2024Dr.Finance S.A., Annual General Meeting, Jun 28, 2024.
Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.95m (up 296% from 1Q 2023). Net loss: zł57.0k (loss widened 400% from 1Q 2023).
Reported Earnings • Feb 11Full year 2023 earnings released: zł0.002 loss per share (vs zł0.053 loss in FY 2022)Full year 2023 results: zł0.002 loss per share (improved from zł0.053 loss in FY 2022). Revenue: zł6.22m (down 17% from FY 2022). Net loss: zł7.7k (loss narrowed 96% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
공고 • Jan 12+ 4 more updatesDr.Finance S.A. to Report Fiscal Year 2023 Results on Nov 07, 2024Dr.Finance S.A. announced that they will report fiscal year 2023 results on Nov 07, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł1.51m (down 1.2% from 3Q 2022). Net income: zł28.1k (up zł33.5k from 3Q 2022). Profit margin: 1.9% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł1.21m (down 43% from 2Q 2022). Net loss: zł41.4k (loss narrowed 47% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
공고 • Jun 13Dr.Finance S.A., Annual General Meeting, Jun 29, 2023Dr.Finance S.A., Annual General Meeting, Jun 29, 2023, at 12:00 Central European Standard Time.
공고 • Jan 12+ 4 more updatesDr.Finance S.A. to Report Q4, 2022 Results on Feb 13, 2023Dr.Finance S.A. announced that they will report Q4, 2022 results on Feb 13, 2023
공고 • Nov 15Dr.Finance S.A. to Report Q3, 2022 Results on Nov 15, 2022Dr.Finance S.A. announced that they will report Q3, 2022 results on Nov 15, 2022
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.04, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 18x in the Capital Markets industry in Poland. Total returns to shareholders of 234% over the past three years.
공고 • Jun 02Dr.Finance S.A., Annual General Meeting, Jun 27, 2022Dr.Finance S.A., Annual General Meeting, Jun 27, 2022, at 10:00 Central European Standard Time.
Reported Earnings • Apr 27First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł2.97m (up 54% from 1Q 2021). Net loss: zł72.1k (loss widened 107% from 1Q 2021).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to zł1.09, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 173% over the past three years.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.041 (up from zł0.004 loss in FY 2020). Revenue: zł11.7m (up 52% from FY 2020). Net income: zł154.5k (up zł168.0k from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to zł1.07, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 161% over the past three years.
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.30, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 16x in the Capital Markets industry in Poland. Total returns to shareholders of 182% over the past three years.
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improved over the past weekAfter last week's 21% share price gain to zł1.39, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 15x in the Capital Markets industry in Poland. Total returns to shareholders of 202% over the past three years.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł1.24, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 14x in the Capital Markets industry in Poland. Total returns to shareholders of 187% over the past three years.
Reported Earnings • Oct 19Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł3.49m (up 79% from 3Q 2020). Net income: zł191.4k (up 460% from 3Q 2020). Profit margin: 5.5% (up from 1.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 151 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 17First quarter 2021 earnings releasedThe company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: zł1.93m (up 12% from 1Q 2020). Net loss: zł34.9k (loss widened 166% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 124 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 17Full year 2020 earnings released: EPS zł0.012 (vs zł0.05 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: zł7.72m (up 7.5% from FY 2019). Net income: zł43.2k (down 77% from FY 2019). Profit margin: 0.6% (down from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.37, the stock is trading at a trailing P/E ratio of 60.4x, up from the previous P/E ratio of 52.5x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 270%.
Valuation Update With 7 Day Price Move • Jan 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to zł1.33, the stock is trading at a trailing P/E ratio of 58.7x, down from the previous P/E ratio of 70.6x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 217%.
공고 • Jan 13+ 2 more updatesDr.Finance S.A. to Report Q3, 2021 Results on Oct 15, 2021Dr.Finance S.A. announced that they will report Q3, 2021 results on Oct 15, 2021
Is New 90 Day High Low • Dec 28New 90-day high: zł1.73The company is up 281% from its price of zł0.45 on 29 September 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł1.73, the stock is trading at a trailing P/E ratio of 76.3x, up from the previous P/E ratio of 66.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 220%.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to zł1.49, the stock is trading at a trailing P/E ratio of 65.7x, up from the previous P/E ratio of 55.6x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 239%.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to zł1.50, the stock is trading at a trailing P/E ratio of 66.2x, up from the previous P/E ratio of 54.2x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 200%.
Valuation Update With 7 Day Price Move • Dec 07Market bids up stock over the past weekAfter last week's 16% share price gain to zł1.28, the stock is trading at a trailing P/E ratio of 56.5x, up from the previous P/E ratio of 48.5x. This compares to an average P/E of 9x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 156%.
Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 15% share price decline to zł1.05, the stock is trading at a trailing P/E ratio of 46.3x, down from the previous P/E ratio of 54.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 102%.
Valuation Update With 7 Day Price Move • Nov 10Market bids up stock over the past weekAfter last week's 24% share price gain to zł1.23, the stock is trading at a trailing P/E ratio of 54.2x, up from the previous P/E ratio of 43.7x. This compares to an average P/E of 11x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 128%.
Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 45% share price gain to zł1.41, the stock is trading at a trailing P/E ratio of 62.2x, up from the previous P/E ratio of 42.8x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 182%.
Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 33% share price decline to zł1.10, the stock is trading at a trailing P/E ratio of 48.5x, down from the previous P/E ratio of 72.8x. This compares to an average P/E of 13x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 112%.
Valuation Update With 7 Day Price Move • Oct 19Market bids up stock over the past weekAfter last week's 79% share price gain to zł1.65, the stock is trading at a trailing P/E ratio of 72.8x, up from the previous P/E ratio of 40.6x. This compares to an average P/E of 12x in the Capital Markets industry in Poland. Total returns to shareholders over the past three years are 206%.
Reported Earnings • Oct 15Third quarter earnings releasedOver the last 12 months the company has reported total profits of zł84.8k, down 53% from the prior year. Total revenue was zł7.29m over the last 12 months, up 5.8% from the prior year.
Is New 90 Day High Low • Oct 12New 90-day high: zł0.92The company is up 109% from its price of zł0.44 on 14 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 6.0% over the same period.